15 completed, 5 terminated, 2 recruiting. 12 Phase 2, 8 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 8, Terminated 3, Recruiting 1 |
| Phase 3 | 8 | Completed 5, Terminated 2, Recruiting 1 |
| Phase 1 | 3 | Completed 3 |
Follow Biotest: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP) Trimodulin, Placebo (human albumin 1%) - Community-acquired Pneumonia | Phase 3 | Recruiting | Biotest | 590 | 2023-09-09 | 2026-09-14 |
| Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia Trimodulin, Placebo (human albumin 1%) - Respiratory Infection, Pneumonia | Phase 3 | Terminated | Biotest | 107 | 2022-12-22 | 2025-06-08 |
| Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation. Cytotect®CP - Cytomegalovirus Infections | Phase 2 | Terminated | University Hospital, Lille | 2 | 2022-09-13 | 2025-09-30 |
| Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®) - Chronic Hepatitis B | Phase 2 | Terminated | Hannover Medical School | 13 | 2022-08-15 | 2025-09-04 |
| Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion) BT097 - Congenital Cytomegalovirus Infection | Phase 3 | Terminated | Biotest | 48 | 2021-11-17 | 2025-03-10 |
| Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection Cytotect - Kidney Transplantation, CMV Infection | Phase 2 | Completed | University Hospital, Bordeaux | 42 | 2021-11-17 | 2026-05-12 |
| Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19 Trimodulin, Placebo (human albumin 1%) - Covid19 | Phase 2 | Completed | Biotest | 166 | 2020-10-06 | 2023-01-10 |
| Adjusted Fibrinogen Replacement Strategy BT524, FFP/Cryo - Bleeding Disorder, Hypofibrinogenemia; Acquired | Phase 3 | Completed | Biotest | 222 | 2018-04-03 | 2025-06-13 |
| Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis Pentaglobin®/Standard of Care - Peritonitis, Sepsis | Phase 2 | Recruiting | RWTH Aachen University | 200 | 2017-11-20 | 2026-06-11 |
| This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP) BT595 - Immune Thrombocytopenia | Phase 3 | Completed | Biotest | 34 | 2016-11-01 | 2019-08-14 |
| Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID IgG Next Generation (BT595) - Primary Immunodeficiency Disease | Phase 3 | Completed | Biotest | 81 | 2016-10-04 | 2023-07-20 |
| Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus BT063, Placebo - Systemic Lupus Erythematosus | Phase 2 | Completed | Biotest | 36 | 2015-09-28 | 2020-01-27 |
| Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis Tregalizumab, Placebo - Rheumatoid Arthritis | Phase 2 | Terminated | Biotest | 321 | 2013-10-01 | 2017-08-24 |
| Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency BT524 (Part I), BT524 (Part II) - Congenital Afibrinogenemia, Congenital Hypofibrinogenemia | Phase 3 | Completed | Biotest | 67 | 2013-03-01 | 2025-07-03 |
| A Clinical Trial of Zutectra in Patients Who Recently Received a Liver Transplant Zutectra - Hepatitis B | Phase 3 | Completed | Biotest | 49 | 2012-12-01 | 2015-03-25 |
| BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma BT062 , intravenous administration - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Biotest Pharmaceuticals Corporation | 64 | 2012-07-03 | 2019-07-23 |
| Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP BT086, 1% Human Albumin infusion - Community Acquired Pneumonia | Phase 2 | Completed | Biotest | 160 | 2011-08-01 | 2015-07-29 |
| Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX) BT061, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Biotest | 127 | 2010-12-01 | 2015-02-20 |
| Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma BT062 - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Biotest Pharmaceuticals Corporation | 35 | 2010-08-01 | 2019-07-30 |
| Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis BT061, placebo treatment - Psoriasis Vulgaris | Phase 2 | Completed | Biotest | 49 | 2010-02-01 | 2012-03-13 |
Showing 20 of 22. Sign in to see all of them.
Community-Acquired Pneumonia (4) · Cytomegalovirus Infections (3) · Multiple Myeloma (3) · Afibrinogenemia (2) · Arthritis, Rheumatoid (2) · COVID-19 (2) · Pneumonia, Bacterial (2) · Recurrence (2) · Respiratory Distress Syndrome (2) · Autoimmune Diseases (1) · Hemorrhage (1) · Hemostatic Disorders (1) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Kidney Failure, Chronic (1)
trimodulin (3) · hepatitis B hyperimmune globulin (2) · indatuximab ravtansine (2) · Administration, Intravenous (1) · Azathioprine (1) · BT088 immunoglobulin, human (1) · Cyclosporine (1) · Fluid Therapy (1) · Immunoglobulins, Intravenous (1) · Kidney Transplantation (1) · Mycophenolic Acid (1) · Solutions (1) · Tacrolimus (1) · cryoprecipitate coagulum (1) · cytomegalovirus-specific hyperimmune globulin (1)
Germany (13) · Spain (9) · Hungary (7) · Czechia (6) · France (6) · United States (6) · Belgium (4) · Poland (4) · United Kingdom (4) · Austria (3) · Brazil (3) · Bulgaria (3) · Russia (3) · Serbia (3) · Argentina (2)
Kenneth C. Anderson, MD (2) · Antoni Torres, MD (1) · Antoni Torres, Prof (1) · Claudia Djambas Khayat, MD (1) · Didier Samuel, Professeur (1) · Gergely Krivan, MD (1) · Gernot Marx, Univ.-Prof. (1) · Heiner Wedemeyer, Prof. (1) · Ibrahim Yakoub-Agha, MD,PhD (1) · Judit Demeter, MD, PhD, DSc (1) · Karl O Kagan, Prof (1) · Kenneth C Anderson, MD (1) · Nemanja Damjanov, Professor (1)
PMID 12270445, PMID 15691277, PMID 15919463, PMID 16771810, PMID 21401729, PMID 24530759, PMID 29343509, PMID 29632995, PMID 30832742, PMID 33351126, PMID 33687069, PMID 34529955, PMID 35944615, PMID 36383294, PMID 36448274, PMID 39138518, PMID 40741224, PMID 41702298, PMID 42247815
2015 (1), 2016 (1), 2017 (1)